Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients [Yahoo! Finance]

Harrow, Inc. (HROW)
Last harrow, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
NASHVILLE, Tenn., April 10, 2025 BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE ® Access for All ("VAFA") program to include patients currently prescribed Klarity-C Drops ® , a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx ® , Harrow's compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access barriers like prior authorization and reimbursement delays, providing free home delivery, and offering a no-questions-asked, money-back guarantee. The VEVYE Access for All program is flexible, allowing patients to choose to us
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)PR Newswire
- Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C PatientsBusiness Wire
- Harrow, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $69.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.MarketBeat
- Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results [Yahoo! Finance]Yahoo! Finance
HROW
Earnings
- 11/13/24 - Miss
HROW
Sec Filings
- 4/25/25 - Form DEFA14A
- 4/25/25 - Form DEF
- 4/7/25 - Form 4
- HROW's page on the SEC website